Barrick Mining Corporation Stock Price, News & Analysis

Inertial Sense (B) agreed to be acquired by Hexagon AB (HEXA B), strengthening Hexagon’s assured Positioning, Navigation, and Timing (PNT) capabilities for autonomy, aerospace, and defense.

Under the agreement, Inertial Sense will join Hexagon’s Autonomous Solutions business area and continue operations there. Inertial Sense has shipped over 30,000 navigation systems worldwide and provides centimeter-level accuracy in compact GNSS+INS products. The transaction is expected to close in the first half of 2026, subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.

B (Barrick) reported Q3 2025 results on Nov 10, 2025: revenue of $4.1B, gold production of 829,000 oz and copper production of 55,000 t. The company delivered record quarterly operating cash flow of $2.4B (+82% vs Q2) and free cash flow of $1.5B (+274% vs Q2). Net earnings were $1.3B ($0.76/share) and adjusted net earnings were $982M ($0.58/share).

The Board raised the base quarterly dividend 25% to $0.125/share and approved a total $0.175 per-share payout this quarter, expanded the buyback program by $500M (YTD repurchases $1.0B), and reiterated full-year 2025 guidance.

Barrick (NYSE:B) announced on November 10, 2025 that its Board approved a $500 million increase to the existing share repurchase program.

In February 2025 the Board authorized repurchases up to $1.0 billion over 12 months; Barrick had repurchased $1.0 billion of shares as of September 30, 2025. The additional $500 million allows for potential further repurchases over the remaining term of the program. Repurchases may occur on public U.S. markets, including the NYSE, and by other SEC‑permitted methods. The Company said actual timing and amounts will depend on financial performance, cash flow availability, capital needs, other shareholder returns, and debt reduction, and that the program may be suspended at any time. The Board will consider any 2026 program in February 2026.

B (Barrick) raised its quarterly base dividend by 25% to $0.125 per share and declared an enhanced Q3 2025 dividend of $0.175 per share (including a $0.05 performance dividend). The Q3 dividend is payable on December 15, 2025 to holders of record on November 28, 2025. Barrick repurchased approximately 18.60 million shares in Q3 and 39.79 million shares year-to-date under the 2025 buyback program, representing about 2.3% of issued shares, for total cash of $1.0 billion (including $589 million in Q3). The company updated its Performance Dividend Policy showing tiered performance payments up to $0.15 per quarter, producing a maximum quarterly total of $0.275 per share.

Cereno Scientific (B) submitted the clinical trial protocol for a planned global Phase IIb study of CS1 in pulmonary arterial hypertension (PAH) to the U.S. FDA on Nov 10, 2025. The submission follows FDA Type C meeting feedback and aims to advance CS1—an oral HDAC inhibitor that targets PAH via epigenetic modulation—after Phase IIa showed favorable safety, tolerability and encouraging efficacy signals (reverse vascular remodeling, improved right heart function, better patient quality of life). The Phase IIb is designed as a global, multicenter, placebo-controlled trial run with an international CRO. Cereno expects the FDA's standard 30-day review and plans to start the trial in H1 2026.

B (Barrick) completed the sale of the Alturas Project in Chile to Boroo Pte. Ltd. for an up-front cash payment of $50 million on Nov 7, 2025. Barrick also retained a 0.5% net smelter return (NSR) royalty on gold and silver from the project that terminates after 2 million ounces gold-equivalent are produced. Boroo has a four-year repurchase option to buy back the royalty for $10 million. The transaction converts the asset to cash and a capped royalty interest.

Helzberg (NYSE:A) will open redesigned stores in New York and Dallas in November 2025, unveiling next‑generation brick-and-mortar concepts that combine digital discovery with hands-on craftsmanship. The new stores feature an interactive custom bar, a visible jeweler's workshop, a larger diamond carat-weight assortment in engagement rings and wedding bands, and an expanded Luxe Jewelry collection.

A company consumer study found 83% of couples say the ability to purchase in-store is important, nearly three in five plan to consult a jeweler and buy in person, 47% rate ring customization as very important, and 76% would invest more in a custom design. Helzberg also highlights digital support via its Love & Marriage Studio for pre-visit education and inspiration.

Metsera (NASDAQ: B) announced its board has declared an amended acquisition proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal values Metsera at up to $86.20 per share (~$10.0B), including an immediate cash payment/dividend of $62.20 per share and a second-step contingent value right (CVR) of up to $24.00 per share. Metsera notified Pfizer, triggering a two-business-day negotiation period under the Pfizer Merger Agreement.

Metsera (NASDAQ: B) announced that its board has declared an amended proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer on Nov 4, 2025. The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share (~$10.0 billion) via a two-step structure: an immediate $62.20 per share cash payment plus non-voting preferred stock, followed by a dividend of $62.20, and a contingent value right (CVR) worth up to $24.00 per share upon regulatory and development milestones.

Metsera notified Pfizer, triggering a two-business-day period for Pfizer to propose adjustments under the Pfizer Merger Agreement; Pfizer previously revised its proposal to $60.00 upfront + up to $10.00 CVR.